Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
A composition and disease technology, applied in the direction of nervous system diseases, drug combinations, active ingredients of heterocyclic compounds, etc., can solve problems such as misfolding
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0200] Characterize Compounds by Accurate Mass, Relative Abundance, and Weight Percent
[0201]The present inventors have surprisingly discovered that a combination of several compounds can prevent and treat Alzheimer's disease, protein aggregation, protein misfolding and inflammation. The present inventors have also discovered that specific relative concentrations of the compounds are used to enhance the ability of the combined compounds to prevent and treat these diseases. Compounds of the invention include curcumin and biomarker compounds defined by compounds found in turmeric with the following exact masses: 120.094 amu (biomarker 1), 134.110 amu (biomarker 2), 150.104 amu (biomarker 3), 176.120 amu (biomarker 4), 192.091 amu (biomarker 5), 200.157 amu (biomarker 6), 202.172 amu (biomarker 7), 204.188 amu (biomarker 8), 216.151 amu (biomarker 9), 218.203 amu ( Biomarker 10), 220.183 amu (Biomarker 11), 232.146 amu (Biomarker 12), 234.162 amu (Biomarker 13), 256.240 amu (B...
Embodiment 2
[0224] Formulations used in Examples 3 to 8
[0225] HSRx-888 (a particular embodiment of the disclosed composition) is generally prepared according to the methods described in Shytle et al., 2009 and Shytle et al., 2012, and it contains a dose-responsible dose of turmeric extract comprising 55% by weight of curcuminoids and bio Markers 1 to 16, 18 and 19 with 0.06 wt% biomarker 3, 2.15 wt% biomarker 15, 2.39 wt% biomarker 16 and 1.26 wt% biomarker 18, and relative abundance of biomarker 1 The relative abundance of biomarker 2 was 3.11%, the relative abundance of biomarker 2 was 0.44%, the relative abundance of biomarker 4 was 1.37%, the relative abundance of biomarker 5 was 2.49%, the relative abundance of biomarker 6 was 0.68%, the relative abundance of biomarker The relative abundance of biomarker 7 was 1.24%, the relative abundance of biomarker 8 was 0.43%, the relative abundance of biomarker 9 was 15.35%, the relative abundance of biomarker 10 was 5.72%, and the relative ...
Embodiment 3
[0228] Serum PK and Tolerability Studies in Human Subjects
[0229] This example relates to data obtained from a study examining the serum pharmacokinetics (PK) of the formulation of Example 2 in normal human volunteer subjects. Volunteer human subjects were administered 50 mg of the formulation orally. The 50 mg formulation contains 35 mg curcumin. After oral administration to 5 human volunteers, blood was drawn at t=0, 5 min, 10 min, 20 min, 30 min, 40 min, 60 min, 120 min, 180 min, 240 min and 480 min and test. Peak intensities for curcumin and / or curcumin and biomarkers 1, 2, 6 and 12 in plasma were determined by DART ToF-MS.
[0230] The peaks at each time point were plotted to determine the maximum concentration of curcumin (C max ) and the maximum concentration time of curcumin and biomarkers 1, 2, 6 and 12 (T max )( Figure 1 to Figure 6 ). Determine C empirically using the average peak intensity at each time point max and T max .
[0231] Determine the free ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| particle diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More